{
  "nctId": "NCT02815540",
  "briefTitle": "The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy",
  "officialTitle": "The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children",
  "protocolDocument": {
    "nctId": "NCT02815540",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2016-09-28",
    "uploadDate": "2021-12-02T11:12",
    "size": 225539,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02815540/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE1",
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 2,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-02-16",
    "completionDate": "2018-12-01",
    "primaryCompletionDate": "2018-12-01",
    "firstSubmitDate": "2016-06-20",
    "firstPostDate": "2016-06-28"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Diagnosed with Dravet syndrome or Lennox-Gastaut syndrome\n* Patients who are planning to obtain medical cannabidiol\n* Patients who are already taking medical cannabidiol and are planning to stop taking it\n\nExclusion Criteria:\n\n* Patients without a diagnosis of Dravet syndrome or Lennox-Gastaut syndrome",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "2 Years",
    "maximumAge": "30 Years",
    "stdAges": [
      "CHILD",
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Holter SDNN Parameter Change",
        "description": "Change from baseline Holter SDNN parameter to follow up visit Holter SDNN parameter.",
        "timeFrame": "Baseline to 4 to 8 week follow up visit"
      }
    ],
    "secondary": [
      {
        "measure": "Seizure Frequency",
        "description": "Change from baseline seizure frequency to follow up visit seizure frequency.",
        "timeFrame": "Baseline and 4 to 8 week follow up visit"
      },
      {
        "measure": "Dysautonomia Signs and Symptoms",
        "description": "signs and symptoms assessed by questionnaire developed for this study that documents observable signs and symptoms of dysautonomia",
        "timeFrame": "Baseline and 4 to 8 week follow up visit"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 2,
      "otherCount": 0,
      "totalCount": 3
    },
    "studyDesign": {
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 34,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-21T22:34:17.999Z",
  "dataSource": "ClinicalTrials.gov API v2 - Mass Collection"
}